Japanese trading and pharmaceutical company Kowa Co. Ltd. said Monday that ivermectin shows an “antiviral effect” against the omicron variant and others.
The statement was based on joint, non-clinical trials the company has been running with Tokyo’s Kitasato University, Just the News reports.
It is no secret that the drug is extremely controversial. It is not approved for use in treating the virus in Japan, and in the U.S., the FDA continues to caution against its use.
While the FDA argues there have been a number of cases in which people were hospitalized after self-medicating with the drug, there have also been several cases of it being used to successfully treat COVID-19 in unvaccinated and vaccinated patients.
Ivermectin is currently being studied in the United Kingdom in a trial through Oxford University.